AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions
Challenges and solutions in PD-L1 testing in NSCLC
Current treatment standards for primary ovarian cancer
Evolving medical treatment in advanced/recurrent endometrial cancer